A fresh $150K in Seed funding is heading to Wavena, the medical AI company aiming to revolutionize diagnostics by predicting blood biomarkers from ECG signals alone. This non-invasive approach, which leverages a proprietary deep learning algorithm, seeks to overcome the inherent limitations of traditional blood tests, offering a potentially less intrusive way to monitor health.
The capital infusion comes from Seoul Techno Holdings, backing Wavena's innovative vision for a future where critical health insights can be gleaned without a needle stick.
